StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for ENSC yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-15 | $0.28 | $0.28 | +1.27% | 0.9M |
| 05-18 | $0.25 | $0.32 | +24.90% | 2.1M |
| 05-19 | $0.30 | $0.30 | -0.27% | 0.8M |
| 05-20 | $0.30 | $0.31 | +3.33% | 1.1M |
| 05-21 | $0.31 | $0.32 | +4.23% | 0.7M |
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $961.00K | $5.07M | $3.18M | $2.69M |
Operating Income | $-3.56M | $-10.24M | $-7.46M | $-3.72M |
Net Income | $-3.56M | $-10.18M | $-7.41M | $-3.68M |
EPS (Diluted) | $-0.52 | $-3.98 | $-3.42 | $-2.04 |
Total Assets | $2.17M | $7.45M | $3.18M | $5.57M |
Total Liabilities | $2.84M | $4.57M | $2.30M | $2.51M |
Cash & Equivalents | $745.48K | $4.31M | $1.67M | $2.21M |
Free Cash Flow OCF − CapEx | Not available | $-7.93M | $-6.40M | Not available |
Shares Outstanding | 9.28M | 4.57M | 3.18M | 2.39M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.